
Aster DM Healthcare Gears Up for Q3 Reveal on 30th January; Check Key Expectations Here
Click and Sign Up to Get Live Updates on Q3 Results
Updated: 29 Jan 2026 • 3:18 pm
Posted by:

Aster DM Healthcare’s Q3 results FY26 are scheduled to be announced on 30th January 2026. Financial analysts anticipate an increase in revenue due to higher sales and a significant rise in PAT.
Aster DM Healthcare Q3 Results 2026 Preview
- Aster DM Healthcare’s revenue is expected to be in the range of ₹1,049.82 crore, a 3.37% YoY decrease.
- Profit After Tax, or PAT, is projected to fall by 41.36% YoY.
- Aster DM Healthcare’s EBITDA is expected to fall to ₹103.25 crore.
- Net profit is ₹56.79 crore, a fall 41.36% YoY
Aster DM Healthcare Share Performance
- Over the past six months, Aster DM Healthcare’s share price has fallen by 8.95% to ₹538.65.
- Moreover, over the past year, the stock has increased by 12.87%.
- Despite this weak short-term performance, Aster DM Healthcare’s stock has delivered a financially sound 239.85% return over the past 5 years.
- As of 29th January 2026, the stock traded at ₹538.05 per share.
Key Factors to Watch for Aster DM Healthcare Q3 Results FY26
- Revenue growth and core hospital demand – Trends in overall sales driven by inpatient volumes, outpatient services, and case mix will reflect demand momentum across the network.
- Operating margins and profitability – Movement in EBITDA and net profit margins will signal cost efficiency and pricing power, especially amid cost control and improved occupancy.
- Capacity utilisation and expansion metrics – Performance of existing beds and contribution from newly added capacity, as well as progress on planned bed additions, will be key for the medium‑term growth outlook.
- Average revenue per occupied bed (ARPOB) and length of stay – ARPOB trends and changes in average length of stay indicate service mix quality and operational efficiency.
- Merger integration & strategic developments – Updates on the Quality Care India Ltd merger, synergies from combined operations, and any regulatory progress will influence future scale and performance.
Final Thoughts
Aster DM Healthcare will announce its Q3 FY26 results on 30th January 2026. Analysts expect 5.27% YoY revenue growth, a 0.95% fall in PAT, and a 5.99% fall in EBITDA. Aster DM Healthcare focuses on expanding hospital and clinic networks, increasing patient volumes, improving operational efficiencies, growing the pharmacy and diagnostics segments, and enhancing digital healthcare services across domestic and international markets.
Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.
Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!
Recent Articles
Capital Small Finance Bank Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Carborundum Universal Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Capri Global Capital Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Digitide Solutions Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Flair Writing Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
GHCL Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Apar Industries Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Apollo Pipes Gears Up for Q3 Reveal on 29th January; Check Key Expectations Here
Recent Articles

Infomedia Press Q1 Results FY27: Company Narrows Loss to Rs 0.93 Crore on Zero Revenue
15 July 2026

L&T Technology Services Q1 Results FY27: PAT Rises 13% to Rs 357 Crore as Revenue Grows 11.47%
15 July 2026

Benares Hotels Q1 Results FY27: PAT Rises 8.8% to Rs 8 Crore as Revenue Jumps 35.48%
15 July 2026

Den Networks Q1 Results FY27: PAT Falls 35.48% to Rs 35 Crore as Gross Profit Turns Negative
15 July 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Infomedia Press Q1 Results FY27: Company Narrows Loss to Rs 0.93 Crore on Zero Revenue
L&T Technology Services Q1 Results FY27: PAT Rises 13% to Rs 357 Crore as Revenue Grows 11.47%
Benares Hotels Q1 Results FY27: PAT Rises 8.8% to Rs 8 Crore as Revenue Jumps 35.48%
Den Networks Q1 Results FY27: PAT Falls 35.48% to Rs 35 Crore as Gross Profit Turns Negative
Viji Finance Q1 Results FY27: Company Swings to Rs 1 Crore Profit as Revenue Jumps 57.11%
Popular this week
Infomedia Press Q1 Results FY27: Company Narrows Loss to Rs 0.93 Crore on Zero Revenue
L&T Technology Services Q1 Results FY27: PAT Rises 13% to Rs 357 Crore as Revenue Grows 11.47%
Benares Hotels Q1 Results FY27: PAT Rises 8.8% to Rs 8 Crore as Revenue Jumps 35.48%
Den Networks Q1 Results FY27: PAT Falls 35.48% to Rs 35 Crore as Gross Profit Turns Negative
Viji Finance Q1 Results FY27: Company Swings to Rs 1 Crore Profit as Revenue Jumps 57.11%

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





